Grape seed extract supplementation in non-alcoholic fatty liver disease

被引:2
|
作者
Ghanbari, Parisa [1 ]
Alboebadi, Roghayeh [1 ]
Bazyar, Hadi [2 ,3 ]
Raiesi, Davoud [4 ]
Zarejavid, Ahmad [5 ]
Azadbakht, Mohammad Karim [6 ]
Karimi, Mahdi [1 ]
Razmi, Hamidreza [1 ]
机构
[1] Ahvaz Jundishapur Univ Med Sci, Student Res Comm, Ahvaz, Iran
[2] Sirjan Sch Med Sci, Dept Publ Hlth, Sirjan, Iran
[3] Student Res Comm, Sirjan Sch Med Sci, Sirjan, Iran
[4] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Internal Med, Ahvaz, Iran
[5] Ahvaz Jundishapur Univ Med Sci, Clin Sci Res Inst, Nutr & Metab Dis Res Ctr, Ahvaz, Iran
[6] Sirjan Sch Med Sci, Dept Basic Sci, Sirjan, Iran
关键词
non-alcoholic fatty liver disease; oxidative stress; quality of life; grape seed extract; ANTIOXIDANT STATUS; OXIDATIVE STRESS; DOUBLE-BLIND; INCREASES; QUESTIONNAIRE; POLYPHENOLS; VALIDATION;
D O I
10.1024/0300-9831/a000805
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Despite rising non-alcoholic fatty liver disease (NAFLD) prevalence and its impact on liver health, there's a lack of studies on grape seed extract's (GSE) effect on oxidative stress and quality of life (QoL) in NAFLD patients. This study aims to fill this gap by the potential benefits of GSE in reducing oxidative stress and improving QoL. Methods: In this randomized clinical trial study, fifty patients with NAFLD were randomly assigned to receive either 2 tablets of GSE containing 250 mg of proanthocyanidins or placebo (25 participants in each group) for two months. QoL was evaluated using the SF-36 questionnaire, and oxidative stress variables (TAC, MDA, SOD, GPx, CAT, and IL-6) were measured at the beginning and end of the study. Results: Compared with the control group, the group supplemented with GSE experienced greater reductions in IL-6 and MDA (3.14 +/- 1.43 pg/ml vs. 2.80 +/- 0.31 pg/ml; 4.16 +/- 2.09 mu M vs. 4.59 +/- 1.19 mu M, p for all <0.05), as well as greater increases in TAC, SOD, and GPx levels (0.18 +/- 0.08 mM vs. -0.03 +/- 0.09 mM; 10.5 +/- 6.69 U/ml vs. 8.93 +/- 1.63 U/ml; 14.7 +/- 13.4 U/ml vs. 8.24 +/- 3.03 U/ml, p for all <0.05). Furthermore, the QoL questionnaire showed that physical limitations, general health, and total physical health were significantly improved in the GSE group compared with the placebo (17.0 +/- 42.0 vs. -12.0 +/- 37.5; 3.80 +/- 14.8 vs. -3.92 +/- 9.55; 5.08 5.26 vs. -7.01 +/- 13.7, p for all <0.05). Conclusions: GSE can be effective in improving oxidative stress and QoL in patients with NAFLD. More studies are needed to confirm the results of this study.
引用
收藏
页码:365 / 376
页数:12
相关论文
共 50 条
  • [21] Psoriasis and non-alcoholic fatty liver disease
    Wenk, K. S.
    Arrington, K. C.
    Ehrlich, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2011, 25 (04) : 383 - 391
  • [22] Iron and non-alcoholic fatty liver disease
    Britton, Laurence J.
    Subramaniam, V. Nathan
    Crawford, Darrell H. G.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (36) : 8112 - 8122
  • [23] Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
    Miyake, Teruki
    Yoshida, Sakiko
    Furukawa, Shinya
    Sakai, Takenori
    Tada, Fujimasa
    Senba, Hidenori
    Yamamoto, Shin
    Koizumi, Yohei
    Yoshida, Osamu
    Hirooka, Masashi
    Kumagi, Teru
    Niiya, Tetsuju
    Miyaoka, Hiroaki
    Masanori, Abe
    Matsuura, Bunzo
    Hiasa, Yoichi
    OPEN MEDICINE, 2018, 13 (01): : 402 - 409
  • [24] Effects of Green Coffee Bean Extract Supplementation on Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial
    Shahmohammadi, Hedayat Allah
    Hosseini, Seyed Ahmad
    Hajiani, Eskandar
    Malehi, Amal Saki
    Alipour, Meysam
    HEPATITIS MONTHLY, 2017, 17 (04)
  • [25] Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Senavirathna, Tharani
    Shafaei, Armaghan
    Lareu, Ricky
    Balmer, Lois
    ANTIOXIDANTS, 2024, 13 (04)
  • [26] Non-alcoholic fatty liver disease pathogenesis: The present and the future
    Petta, S.
    Muratore, C.
    Craxi, A.
    DIGESTIVE AND LIVER DISEASE, 2009, 41 (09) : 615 - 625
  • [27] Non-alcoholic Fatty Liver Disease: Beneficial Effects of Flavonoids
    Akhlaghi, Masoumeh
    PHYTOTHERAPY RESEARCH, 2016, 30 (10) : 1559 - 1571
  • [28] Experimental models of non-alcoholic fatty liver disease in rats
    Kucera, Otto
    Cervinkova, Zuzana
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (26) : 8364 - 8376
  • [29] Non-alcoholic fatty liver disease and flavonoids: Current perspectives
    Shin, Jung Hee
    Jung, Ji Hye
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2017, 41 (01) : 17 - 24
  • [30] Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease
    Dallio, Marcello
    Diano, Nadia
    Masarone, Mario
    Gravina, Antonietta Gerarda
    Patane, Vittorio
    Romeo, Mario
    Di Sarno, Rosa
    Errico, Sonia
    Nicolucci, Carla
    Abenavoli, Ludovico
    Scarpellini, Emidio
    Boccuto, Luigi
    Persico, Marcello
    Loguercio, Carmelina
    Federico, Alessandro
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2019, 16 (17)